CO6410282A2 - Formulaciones orales sólidas de una pirido-pirimidinona - Google Patents

Formulaciones orales sólidas de una pirido-pirimidinona

Info

Publication number
CO6410282A2
CO6410282A2 CO11095154A CO11095154A CO6410282A2 CO 6410282 A2 CO6410282 A2 CO 6410282A2 CO 11095154 A CO11095154 A CO 11095154A CO 11095154 A CO11095154 A CO 11095154A CO 6410282 A2 CO6410282 A2 CO 6410282A2
Authority
CO
Colombia
Prior art keywords
solid oral
pyridoid
pyrimidinone
oral formulations
pyrido
Prior art date
Application number
CO11095154A
Other languages
English (en)
Inventor
Daya Verma
Yue Helen Teng
Rajinder Sing
Dan Thompson
Original Assignee
Novartis Int Pharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42125930&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO6410282(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Int Pharm Ltd filed Critical Novartis Int Pharm Ltd
Publication of CO6410282A2 publication Critical patent/CO6410282A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nanotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Extraction Or Liquid Replacement (AREA)
  • Pyridine Compounds (AREA)
  • Centrifugal Separators (AREA)

Abstract

Una formulación farmacéutica de dosificación oral sólida de la (R)-2-amino-7-[4-fluoro-2-(6-metoxi-piridin-2-il)-fenil]-4-metil-7,8-dihidro-6H-pirido-[4,3-d]-pirimidin-5-ona o su sal; y un tensoactivo o un ácido.
CO11095154A 2009-01-29 2011-07-28 Formulaciones orales sólidas de una pirido-pirimidinona CO6410282A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US14816009P 2009-01-29 2009-01-29

Publications (1)

Publication Number Publication Date
CO6410282A2 true CO6410282A2 (es) 2012-03-30

Family

ID=42125930

Family Applications (1)

Application Number Title Priority Date Filing Date
CO11095154A CO6410282A2 (es) 2009-01-29 2011-07-28 Formulaciones orales sólidas de una pirido-pirimidinona

Country Status (22)

Country Link
US (2) US20110287069A1 (es)
EP (1) EP2391346A1 (es)
JP (1) JP2012516346A (es)
KR (1) KR20110115592A (es)
CN (1) CN102300559A (es)
AR (1) AR075180A1 (es)
AU (1) AU2010208270B2 (es)
BR (1) BRPI1007515A2 (es)
CA (1) CA2749533A1 (es)
CO (1) CO6410282A2 (es)
EC (1) ECSP11011286A (es)
IL (1) IL213872A0 (es)
MA (1) MA33061B1 (es)
MX (1) MX2011007986A (es)
NZ (1) NZ594035A (es)
PE (1) PE20120422A1 (es)
RU (1) RU2011135424A (es)
SG (2) SG10201500697WA (es)
TN (1) TN2011000351A1 (es)
TW (1) TW201031411A (es)
WO (1) WO2010088336A1 (es)
ZA (1) ZA201104894B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3002B1 (ar) 2009-08-28 2016-09-05 Irm Llc مركبات و تركيبات كمثبطات كيناز بروتين
WO2012104823A2 (en) 2011-02-04 2012-08-09 Novartis Ag Pyridopyrimidinone compounds in the treatment of neurodegenerative diseases
CA2855243C (en) 2011-11-11 2020-04-14 Novartis Ag Method of treating a proliferative disease
AU2012340759C1 (en) 2011-11-23 2019-11-28 Array Biopharma Inc. Pharmaceutical formulations
GB201306610D0 (en) * 2013-04-11 2013-05-29 Almac Discovery Ltd Pharmaceutical compounds
WO2018187849A1 (en) * 2017-04-13 2018-10-18 Pharmako Biotechnologies Pty Limited Cold-water-dispersible chemical delivery system
WO2018237327A1 (en) 2017-06-22 2018-12-27 Triact Therapeutics, Inc. METHODS OF TREATING GLIOBLASTOMA
US11628144B2 (en) 2017-09-29 2023-04-18 Triact Therapeutics, Inc. Iniparib formulations and uses thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
JP2001523221A (ja) * 1996-09-01 2001-11-20 ファーモス コーポレイション 親油性物質の促進された生物学的利用能のための固形共沈物
US6982281B1 (en) * 2000-11-17 2006-01-03 Lipocine Inc Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
GB0119480D0 (en) * 2001-08-09 2001-10-03 Jagotec Ag Novel compositions
JP2005523262A (ja) * 2002-02-01 2005-08-04 ファイザー・プロダクツ・インク 薬物及び親油性ミクロ相形成物質の非晶質分散物の医薬組成物
US20050096365A1 (en) * 2003-11-03 2005-05-05 David Fikstad Pharmaceutical compositions with synchronized solubilizer release
JP4977611B2 (ja) * 2004-09-24 2012-07-18 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド 新規な種類の界面活性剤様物質
CA2601762A1 (en) * 2005-02-03 2006-08-10 Pfizer Products Inc. Dosage forms providing controlled and immediate release of cholesteryl ester transfer protein inhibitors and immediate release of hmg-coa reductase inhibitors
JO2783B1 (en) * 2005-09-30 2014-03-15 نوفارتيس ايه جي Compounds 2-Amino-7, 8-dihydro-6H-Bayredo (3,4-D) Pyrimidine-5-Ones
WO2007056424A2 (en) * 2005-11-07 2007-05-18 Penwest Pharmaceuticals, Co. Controlled-release emulsion compositions
US20070128289A1 (en) * 2005-12-07 2007-06-07 Zhao Jonathon Z Nano-and/or micro-particulate formulations for local injection-based treatment of vascular diseases
AU2006326130B2 (en) * 2005-12-14 2011-09-22 F. Hoffmann-La Roche Ag HCV prodrug formulation
EP2083799A1 (en) * 2006-10-20 2009-08-05 Solvay Pharmaceuticals B.V. Micellar nanoparticles of chemical substances
MX2009011681A (es) * 2007-05-18 2009-11-10 Scidose Llc Formulaciones de ziprasidona.
BRPI0818003A2 (pt) * 2007-10-18 2019-09-24 Novartis Ag inibidores de csf-1r, composições e métodos de uso

Also Published As

Publication number Publication date
SG172813A1 (en) 2011-08-29
IL213872A0 (en) 2011-07-31
CA2749533A1 (en) 2010-08-05
PE20120422A1 (es) 2012-05-03
AR075180A1 (es) 2011-03-16
ZA201104894B (en) 2012-03-28
MA33061B1 (fr) 2012-02-01
JP2012516346A (ja) 2012-07-19
RU2011135424A (ru) 2013-03-10
ECSP11011286A (es) 2011-09-30
KR20110115592A (ko) 2011-10-21
US20140044788A1 (en) 2014-02-13
TW201031411A (en) 2010-09-01
BRPI1007515A2 (pt) 2016-02-23
CN102300559A (zh) 2011-12-28
EP2391346A1 (en) 2011-12-07
NZ594035A (en) 2013-09-27
US20110287069A1 (en) 2011-11-24
AU2010208270A1 (en) 2011-07-21
WO2010088336A1 (en) 2010-08-05
TN2011000351A1 (en) 2013-03-27
SG10201500697WA (en) 2015-04-29
AU2010208270B2 (en) 2014-01-16
MX2011007986A (es) 2011-08-15

Similar Documents

Publication Publication Date Title
ECSP11011286A (es) Formulaciones orales sólidas de una pirido-pirimidinona
RS53209B (en) PHARMACEUTICAL COMPOSITION FOR VIRAL HEPATITIS C PROTEASE INHIBITOR
ECSP12012208A (es) Formulaciones orales y sales lipofílicas de metilnaltrexona
JP2012087153A5 (es)
HK1131918A1 (en) Oral pharmaceutical formulations comprising salts of fenofibric acid
RS54123B1 (en) THERAPEUTIC COMBINATION CONTAINING DOLUTEGRAVIR, ABACAVIR AND LAMIVUDINE
CU20080052A7 (es) Formas de presentación farmacéutica sólidas de administración oral con liberación rápida de principio activo
AR062000A1 (es) Formulaciones de modificador de respuesta inmune
SMT201400076B (it) Formulazioni farmaceutiche contro l'uso improprio di medicinali
CR20110110A (es) Composicion farmaceutica
UA110642C2 (uk) Композиція гербіциду і сафенеру
NO20080220L (no) Formuleringer med hoy medikament belastning og doseringsformer
UA105229C2 (uk) Фармацевтичний склад
BRPI1009392A2 (pt) "formulação farmacêutica, e, uso de uma quantidade farmaceuticamente eficaz de uma formulação farmacêutica."
RS54238B1 (en) ORAL FILM FORMULATIONS CONTAINING DAPOXETINE AND TADALAFIL
UY32424A (es) Comprimidos conteniendo elivitegravir para tratamiento de infecciones virales
EA201201202A1 (ru) Пероральная фармацевтическая композиция, содержащая этексилат дабигатрана
AU2012280198A8 (en) Darunavir combination formulations
EA201200616A1 (ru) Производные 2-оксо-1-пирролидинилимидазотиадиазола
BR112014000195A2 (pt) formulações de darunavir
ECSP10010576A (es) Formulaciones orales e inyectables de compuestos de tetraciclina
ITFI20050041A1 (it) Idrossammati come inibitori dell'istone deacelitasi, loro preparazione e formulazioni farmaceutiche che li contengono
WO2011142731A3 (en) Formulations comprising a third generation cephalosporin and clavulanic acid
WO2012074830A3 (en) Modified release tranexamic acid formulation
EA201291014A1 (ru) Трициклическое индазольное соединение, способ его получения и содержащая его фармацевтическая композиция

Legal Events

Date Code Title Description
FC Application refused